• 
  Reducing R&D from Two Years to a Few Weeks: Discovering Conditions for High-Yield Structural Protein Production with AI
• 
  Searching for cell recipes for regenerative medicine using AI. Achieving efficiency equal to or greater than that of an expert.
• 
  Pioneering the future of cell culture with “CellTune”

Track Record Across the Life Sciences Industry

We have a strong track record of delivering results across a range of life sciences domains.
Here are some of the measurable impacts we’ve made:

Media Development for Antibody Drug Manufacturing

Antibody Yield Improved by 40%

Using our AI-driven optimization engine Epistra Accelerate, integrated into the media optimization support software CellTune, we improved the composition of feed media for antibody production. As a result, we discovered a composition that increased antibody yield by approximately 40% compared to the baseline.

Optimization of Novel Assay Conditions

Sensitivity Improved by 46%,

R&D Time Reduced by 44%

We conducted assay optimization for drug screening. Conditions discovered by Epistra Accelerate outperformed both the pre-optimization baseline (by 46%) and those found by human researchers (by 12%). In addition, AI-driven optimization completed in 2.5 months—reducing the R&D period by 44% compared to human-led efforts (4.5 months).

Performance Improvement in Cell Storage Reagents

Yield Improved by 133%

Functionality by 40%

We developed a high-performance cryopreservation reagent for cell therapy applications. Compared to commercially available alternatives, our optimized formulation increased cell recovery yield by 133% and enhanced cell functionality by 40%. It also demonstrated strong robustness to temperature and concentration variations while avoiding existing IP constraints.

Reduction in Media Costs

Cost Reduced by 70%

Media costs for pharmaceutical manufacturing can be significant. By maintaining comparable performance while minimizing raw material cost, we reduced total media costs by 70%—resulting in estimated annual savings of over 400 million JPY.

Animal-Origin-Free Media Development

Higher Yield

and Full AOF Compliance

Using Epistra Accelerate, we optimized MSC culture media to achieve higher proliferative performance while reducing raw material costs. All developed media are Animal-Origin-Free (AOF), containing no animal- or human-derived components.